Skip to main content
. 2021 Jan 6;11(1):31. doi: 10.3390/jpm11010031

Figure 3.

Figure 3

Evaluation of plasma miRNA expression as diagnostic biomarkers. (a) Relative quantification revealed that miR-210 showed increased expression in plasma samples from breast cancer (BC) patients vs. the control group. (b) The miR-152 also showed increased expression in plasma samples from women with BC vs. the control group. No significant difference was observed between the BC group and benign breast conditions (BBC) for any miRNA. Significant value in Kruskal–Wallis and Dunn’s post test (±SEM - standard error of the mean; * p < 0.05, ** p < 0.01).